ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting

    Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis

    Maria Martin-Lopez1, Eliseo Albert2, Esther Rodriguez-Almaraz3, Isidoro Gonzalez-Alvaro4, Mario Fernandez-Ruiz5, Jose M. Aguado5, David Navarro2 and Jose L. Pablos6, 1Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, 2Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 5Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, 6Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain

    Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
  • Abstract Number: 48 • 2018 ACR/ARHP Annual Meeting

    In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis

    Numa Simons1, Andrey Kruglov2, Yannick Degboe3, Arnaud Constantin3, Sergei Nedospasov4, Alain Cantagrel5, Jean-Luc Davignon6 and Benjamin Rauwel6, 1Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 2German Rheumatism Research Centre, Berlin, Germany, 3Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, 44Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation, 5Center of Rheumatology of CHU, Toulouse, France, 6CPTP, INSERM UMR 1043, Toulouse, France

    In vivo demonstration of tmTNF reverse signaling: significance in the therapeutic response to anti-TNF agents during murine arthritis. N. Simons1,2, A. Kruglov 3, Y. Degboé 1,2, A.…
  • Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting

    Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer

    Xerxes Pundole1, Natalia Zamora2, Harish Siddhanamatha3, Jean Tayar4, Cheuk Hong Leung5, Heather Lin6 and Maria Suarez-Almazor7, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 3The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, 4Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, 5Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 6Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 7Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
  • Abstract Number: 2520 • 2018 ACR/ARHP Annual Meeting

    Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis

    Lea Lopez1, Christophe Richez2, Marie-Elise Truchetet2, Bernard Bannwarth3, Thomas Barnetche4 and Thierry Schaeverbeke5, 1Aquitaine, Bordeaux, Bordeaux, France, 2Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHU de Bordeaux, Bordeaux, France, 4Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, 5Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France

    Background/Purpose: Recent randomized clinical trials (RCTs) have shown similar efficacy of biosimilar agents compared to reference agents. Is the efficacy of reference biologic agents different…
  • Abstract Number: 6L • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study

    Ronald van Vollenhoven1, Bevra H. Hahn2, George C. Tsokos3, Carrie Wagner4, Peter Lipsky5, Benjamin Hsu4, Marc Chevrier4, Robert Gordon4, Manon Triebel6 and Shawn Rose4, 1Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 2UCLA David Geffen School of Medicine, Los Angeles, CA, 3Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4Janssen Research & Development, LLC, Spring House, PA, 5Ampel BioSolutions LLC, Charlottesville, VA, 6Janssen Biologics Europe, Leiden, Netherlands

    Background/Purpose: The IL-12/23 pathway has been implicated in the pathogenesis of SLE. The anti-IL12/23 monoclonal antibody ustekinumab (UST) is efficacious in the treatment of psoriasis,…
  • Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting

    The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study

    Kyosuke Hattori1, Yuji Hirano1, Yasuhide Kanayama2, Nobunori Takahashi3, Naoki Ishiguro3 and Toshihisa Kojima3, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 3Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
  • Abstract Number: 1007 • 2017 ACR/ARHP Annual Meeting

    Smoking Signicantly Reduces Effectiveness and Long-Term Survival of Biologic Treatment in Patients with Rheumatoid Arthritis

    Roger Rolon Campuzano1, Andrea Lujan Coronel Ale1, Osvaldo Luis Cerda1, Fernando Dal Pra1, Emilce E Schneeberger1, María de los Angeles Correa2, Marcos Rosemffet1, Emilio Buschiazzo3, Rodrigo Garcia Salinas4, Silvia Papasidero5, Belén Barrios5, Hernán Maldonado Ficco6 and Gustavo Citera7, 1Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 2Section Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 3Section of Rheumatology, Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, 4Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, 5Section of Rheumatology, Hospital General de Agudos “Dr. E. Tornú”, Buenos Aires, Argentina, Buenos Aires, Argentina, 6section of Rheumatology, Clinica Regional del Sud, Córdoba, Argentina, Córdoba, Argentina, 7Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina

    Background/Purpose: The introduction of biological agents has been an important advance in the treatment of RA. However, they are not exempt from adverse events and…
  • Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting

    Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial

    Atul A. Deodhar1, John D. Reveille2, Eric K. H. Chan3, Steven Peterson4, Nan Li4, Elizabeth C. Hsia5, Lilianne Kim4, Kim Hung Lo4, Diane D. Harrison4 and Chenglong Han6, 1Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 2University of Texas McGovern Medical School, Houston, TX, 3Janssen Global Services, LLC, Raritan, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, 6Janssen Global Services, LLC, Malvern, PA

    Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
  • Abstract Number: 2285 • 2017 ACR/ARHP Annual Meeting

    Treatment of Adult Juvenile Idiopathic Arthritis Patients with Biologic Agents. Data from the National Registry

    Katerina Jarosova1, Lenka Szczukova2, Zlatuse Kristkov3 and Jiri Vencovsky4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, 3Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, 4Institute of Rheumatology, Prague 2, Czech Republic

    Background/Purpose: To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA). Methods: ATTRA is a Czech national registry…
  • Abstract Number: 379 • 2017 ACR/ARHP Annual Meeting

    H Syndrome: Five New Cases from the United States with Novel Features and Responses to Therapy

    Jessica Bloom1, Clara Lin2, Lisa F. Imundo3, Stephen Guthery4, Shelly Stepenaskie5, Csaba Galambos6, Amy Lowichik7 and John F. Bohnsack8, 1Pediatrics, Children's Hospital Colorado, Aurora, CO, 2Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, 3Pediatrics, Columbia University Medical Center, New York, NY, 4Department of Pediatrics,, University of Utah, Salt Lake City, UT, 5Pathology and Dermatology, University of New Mexico, Albuquerque, NM, 6Pathology, Children's Hospital Colorado, Aurora, CO, 7Pathology, University of Utah, Salt Lake City, UT, 8Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT

    Background/Purpose: H Syndrome is an autosomal recessive disorder characterized by cutaneous hyperpigmentation, hypertrichosis, and induration with numerous systemic manifestations. The syndrome is caused by mutations…
  • Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting

    Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic

    Wendy Ramey1, Kristine M. Lohr2, Matt Zeltner1, Haley Herrell Postonl1, Andrew Johannemann1, Aric D. Schadler1 and Aleksander Lenert3, 1University of Kentucky, Lexington, KY, 2Rheumatology, University of Kentucky, Lexington, KY, 3Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY

    Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
  • Abstract Number: 1532 • 2017 ACR/ARHP Annual Meeting

    Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year

    John D. Reveille1, Atul A. Deodhar2, Diane D. Harrison3, Lilianne Kim3, Kim Hung Lo3 and Elizabeth C. Hsia4, 1University of Texas McGovern Medical School, Houston, TX, 2Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA

    Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…
  • Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting

    Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections

    Joost Swart1, Gabriella Giancane1,2, Elio Castagnola1, Andreas Groll1, Gerd Horneff1, Hans-Iko Huppertz1, Daniel J Lovell3, Tom Wolfs1, Michaël Hofer1, Ekaterina Alexeeva1, Violeta Vladislava Panaviene1, Susan Nielsen1, Jordi Anton1, Florence Uettwiller1, Valda Stanevicha1, Maria Trachana1, Fabrizio De Benedetti1, Constantin Ailioaie1, Elena Tsitsami1, Sylvia S.M. Kamphuis1, Troels Herlin1, Pavla Dolezalová1, Gordana Susic1, Berit Flato1, Flavio Sztajnbok1, Elena Fueri4, Francesca Bovis5, Francesca Bagnasco1, Angela Pistorio1, Alberto Martini6, Nico Wulffraat7 and Nicolino Ruperto6, 1Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, 2Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, 3Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, 4Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, 5Università degli Studi di Genova, Genoa, Italy, 6Istituto Giannina Gaslini, Genoa, Italy, 7Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands

    Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…
  • Abstract Number: 425 • 2017 ACR/ARHP Annual Meeting

    Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry

    Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose: To report the prevalence and efficacy of biologic DMARD (bDMARD) monotherapy in real life treatment of rheumatoid arthritis (RA). Methods: RA patients registered in…
  • Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting

    Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor

    Aliza Matusevich1, Maria Suarez-Almazor1, Scott B. Cantor2 and Maria A. Lopez-Olivo1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology